{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'consequences may include severe hypersensitivity-type reactions and decrease in efficacy (PK', 'and/or PD neutralization) due to development of neutralizing ADA (Casadevall, 2002; Li, 2001).', 'Of the 261 patients with PNH who were treated with ravulizumab in the ravulizumab IV clinical', 'studies, 1 patient developed a treatment-emergent ADA. Treatment-emergent ADAs have been', 'observed in 3 healthy subjects treated with ravulizumab subcutaneous (SC) and 1 healthy subject', 'treated with ravulizumab IV in Study ALXN1210-HV-104. All ADA positive titer values were', 'low and negative for eculizumab cross-reactivity. There was no apparent impact of', 'immunogenicity on the PK or PD of ravulizumab. More information about the immunogenicity', \"of ravulizumab may be found in the current edition of the Investigator's Brochure (IB).\", 'Monitoring of immunogenicity for this study will be conducted as described in Section 1.3 and', 'Section 8.2.4.3.', '2.4.1.2.2. Local and Systemic Reactions', 'Protein therapies administered IV have the potential risk of causing local (infusion-site reactions)', 'and systemic reactions (infusion-associated reactions). Infusion-site reactions are those localized', 'to the site of IV drug administration and may include reactions such as erythema, pruritus, and', 'bruising. Infusion-associated reactions are those which are systemic in nature and which may be', 'immune or nonimmune-mediated, generally occurring within hours of drug administration.', 'Immune-mediated reactions may include allergic reactions (eg, anaphylaxis), while', 'nonimmune-mediated reactions are nonspecific (eg, headache, dizziness, nausea). Monitoring for', 'these reactions will be conducted as part of routine safety assessments for this study', '(Section 8.3.7).', '2.4.1.2.3. Pregnancy Exposure', 'No studies of ravulizumab have been conducted in pregnant women. Pregnant or nursing patients', 'will be excluded from the clinical study. Patients enrolled in the study, and their', 'spouses/partners, will use a highly effective or acceptable method of contraception as required in', 'Section 10.4 (Appendix 4). In the event of a pregnancy, the patient will be discontinued from', 'study drug (Section 7).', 'More detailed information about the known and expected benefits and risks and reasonably', 'expected adverse events of ravulizumab may be found in the IB.', 'Page 29 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '3.', 'OBJECTIVES AND ENDPOINTS', 'Objectives', 'Enppoints', 'Primary', 'To assess the efficacy of ravulizumab compared with', 'Change from Baseline in MG-ADL total score at', 'placebo in the treatment of gMG based on the', 'Week 26 of the Randomized-Controlled Period.', 'improvement in the Myasthenia Gravis-Activities of', 'Daily Living (MG-ADL) profile.', 'Secondary', 'To assess the efficacy of ravulizumab compared', 'Change from Baseline in QMG total score at', 'with placebo in the treatment of gMG based on', 'Week 26.', 'the improvement in the Quantitative Myasthenia', 'Gravis (QMG) total score.', 'To assess the efficacy of ravulizumab compared', 'Change from Baseline in the Revised', 'with placebo in the treatment of gMG based on', '15-Component Myasthenia Gravis Quality of Life', 'the improvement in quality of life measures.', '(MG-QOL15r) score at Week 26.', 'Change from Baseline in Neuro-QOL Fatigue', 'score at Week 26.', 'To assess the efficacy of ravulizumab compared', 'Improvement of at least 3 points in the MG-ADL', 'with placebo in the treatment of gMG based on', 'total score from Baseline at Week 26.', 'other efficacy endpoints.', 'Improvement of at least 5 points in the QMG total', 'score from Baseline at Week 26.', 'Exploratory', 'To assess the efficacy of ravulizumab in the', 'Change from Baseline in the Myasthenia Gravis', 'treatment of gMG based on other efficacy', 'Composite (MGC) score at Week 26.', 'endpoints throughout the study.', 'Myasthenia Gravis Foundation of America', '(MGFA) Post-Intervention Status (PIS) at', 'Week 26.', 'Change from Baseline in Euro Quality of Life', '(EQ-5D-5L) at Week 26.', 'Change from baseline in MG-ADL subcomponent', 'scores (bulbar, limbs, respiratory, and ocular) at', 'Week 26.', 'Change from baseline in QMG subcomponent', 'scores (bulbar, limbs, respiratory, and ocular) at', 'Week 26.', 'Incidence of hospitalizations/MG-related', 'hospitalizations.', 'Incidence of Clinical Deterioration/MG crisis.', 'PK/PD/Immunogenicity', 'To evaluate the PK/PD and immunogenicity of', 'Change in serum ravulizumab concentration over', 'ravulizumab in the treatment of gMG throughout', 'time.', 'the study.', 'Change in serum free C5 concentration over time.', 'Incidence of treatment-emergent antidrug', 'antibodies over time.', 'Safety', 'To characterize the overall safety of ravulizumab in', 'Incidence of adverse events and serious adverse', 'the treatment of gMG.', 'events over time.', 'Changes from Baseline in vital signs and', 'laboratory assessments.', 'The above endpoints will be evaluated over time throughout the study.', 'Page 30 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}